Eli Lilly - 51 Year Stock Price History | LLY

Historical daily share price chart and data for Eli Lilly since 1972 adjusted for splits. The latest closing stock price for Eli Lilly as of May 31, 2023 is 429.46.
  • The all-time high Eli Lilly stock closing price was 442.38 on May 19, 2023.
  • The Eli Lilly 52-week high stock price is 454.95, which is 5.9% above the current share price.
  • The Eli Lilly 52-week low stock price is 283.11, which is 34.1% below the current share price.
  • The average Eli Lilly stock price for the last 52 weeks is 344.90.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Eli Lilly Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2023 362.4291 362.8633 442.3800 309.8241 429.4600 18.08%
2022 304.0044 266.5386 372.5764 231.1675 363.7084 34.24%
2021 218.9625 159.9168 273.7089 158.7767 270.9428 66.08%
2020 142.4112 125.2195 166.8063 113.3438 163.1442 31.06%
2019 109.5725 107.0133 125.4279 100.5613 124.4808 15.48%
2018 86.3324 76.9517 110.5158 67.4373 107.7958 40.45%
2017 73.7945 66.0652 79.8688 66.0475 76.7518 17.83%
2016 66.8014 71.4758 73.0816 58.4226 65.1354 -10.37%
2015 67.1760 58.8676 77.1265 57.8920 72.6747 25.37%
2014 51.0615 41.2595 61.1950 41.2595 57.9685 39.75%
2013 42.0756 38.8286 46.1652 38.3824 41.4791 7.24%
2012 33.4711 31.3062 41.7667 29.1908 38.6796 24.27%
2011 26.9104 24.8434 31.2688 24.2098 31.1265 25.15%
2010 24.3041 24.0553 26.6424 22.2779 24.8718 3.71%
2009 22.4410 25.7699 25.7699 17.6817 23.9815 -6.25%
2008 28.2383 31.9625 34.7786 18.9987 25.5794 -21.23%
2007 33.2493 30.8246 36.0067 29.8580 32.4734 5.65%
2006 32.0323 32.8490 34.1118 29.3050 30.7361 -5.16%
2005 31.0785 31.3334 34.0720 28.2875 32.4080 2.52%
2004 36.2732 38.8368 41.7711 27.9188 31.6119 -17.55%
2003 34.2823 35.3490 40.2815 28.8200 38.3407 13.14%
2002 34.2650 41.0825 42.4006 25.4231 33.8868 -17.56%
2001 41.4495 47.2348 47.2348 37.6042 41.1034 -14.44%
2000 40.3829 33.3713 55.6542 27.8586 48.0402 41.92%
1999 38.2681 43.2367 49.1171 31.2102 33.8498 -24.25%
1998 35.7097 34.2745 45.6901 29.0474 44.6846 29.08%
1997 25.9490 17.7079 34.7717 17.7079 34.6176 94.15%
1996 15.2527 13.2348 19.3566 11.8296 17.8300 32.64%
1995 9.4549 7.5354 13.5025 7.2617 13.4428 77.39%
1994 6.3808 6.5554 7.5782 5.3007 7.5782 15.60%
1993 5.5745 6.4635 6.6923 4.7639 6.5554 2.47%
1992 7.0867 8.6582 8.8867 6.1452 6.3972 -24.89%
1991 7.8192 7.2668 8.6582 6.8922 8.5174 16.41%
1990 7.0787 6.6787 8.8649 5.8050 7.3167 9.95%
1989 5.4672 4.0591 6.6544 4.0591 6.6544 64.17%
1988 3.8806 3.6738 4.3151 3.2707 4.0534 12.81%
1987 4.0294 3.3979 4.7878 2.8373 3.5932 5.75%
1986 3.1944 2.5113 3.7755 2.3282 3.3979 33.18%
1985 1.9407 1.4846 2.5513 1.4816 2.5513 68.94%
1984 1.3933 1.3615 1.5303 1.2356 1.5102 14.03%
1983 1.4335 1.3129 1.5646 1.2985 1.3244 0.66%
1982 1.3021 1.2757 1.4873 1.0640 1.3157 2.68%
1981 1.3346 1.4415 1.5617 1.0667 1.2814 -11.97%
1980 1.2194 1.3271 1.4557 1.0553 1.4557 6.71%
1979 1.2655 1.0983 1.4530 1.0896 1.3642 24.86%
1978 1.0296 0.8638 1.2299 0.8409 1.0926 26.05%
1977 0.8879 1.0782 1.0782 0.7523 0.8668 -20.45%
1976 1.1802 1.1697 1.3729 0.9981 1.0896 -7.75%
1975 1.5046 1.5358 1.8104 1.1642 1.1812 -24.09%
1974 1.5868 1.6791 1.8790 1.2871 1.5560 -8.10%
1973 1.8674 1.8104 2.0964 1.6045 1.6932 -7.06%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $405.567B $28.541B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $401.167B 15.18
Novo Nordisk (NVO) Denmark $361.645B 42.06
Merck (MRK) United States $277.012B 16.20
AbbVie (ABBV) United States $240.720B 10.31
Pfizer (PFE) United States $208.933B 5.98
Novartis AG (NVS) Switzerland $204.647B 15.18